Earnings
Advanced Medical Solutions Group plc announces its unaudited interim results for the six months ended 30 June 2019.
Proceeds to fund multi-centre study of STAR Mapping to improve outcomes of persistent Atrial Fibrillation treatment
4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.
A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
Evotec SE reported financial results and corporate updates for the first half of 2019.
PRESS RELEASES